Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Interpace Biosciences's revenue for the twelve months ending Jun 30, 2026 was $36.14M, down 20.5% year over year. For fiscal 2025 it was $38.73M, down 17.5% from the year before. Over ten years it grew 15.2% a year on average. The highest annual figure on record is $157.29M in fiscal 2011.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.73M | -17.5% |
| FY2024 | Dec 31, 2024 | $46.93M | +17.2% |
| FY2023 | Dec 31, 2023 | $40.04M | +25.7% |
| FY2022 | Dec 31, 2022 | $31.84M | +288.4% |
| FY2021 | Dec 31, 2021 | $8.20M | -74.7% |
| FY2020 | Dec 31, 2020 | $32.40M | +33.8% |
| FY2019 | Dec 31, 2019 | $24.22M | +10.6% |
| FY2018 | Dec 31, 2018 | $21.90M | +37.7% |
| FY2017 | Dec 31, 2017 | $15.90M | +21.5% |
| FY2016 | Dec 31, 2016 | $13.09M | +38.7% |
| FY2015 | Dec 31, 2015 | $9.43M | +539.9% |
| FY2014 | Dec 31, 2014 | $1.47M | -99.0% |
| FY2013 | Dec 31, 2013 | $146.53M | +15.5% |
| FY2012 | Dec 31, 2012 | $126.90M | -19.3% |
| FY2011 | Dec 31, 2011 | $157.29M | +16.9% |
| FY2010 | Dec 31, 2010 | $134.59M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.13M | -1.1% |
| Q1 FY2026 | Mar 31, 2026 | $9.03M | -21.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.22M | -25.7% |
| Q3 FY2025 | Sep 30, 2025 | $8.76M | -28.8% |
| Q2 FY2025 | Jun 30, 2025 | $9.23M | -23.3% |
| Q1 FY2025 | Mar 31, 2025 | $11.52M | +13.1% |
| Q4 FY2024 | Dec 31, 2024 | $12.41M | +22.5% |
| Q3 FY2024 | Sep 30, 2024 | $12.30M | +33.6% |
| Q2 FY2024 | Jun 30, 2024 | $12.04M | +9.0% |
| Q1 FY2024 | Mar 31, 2024 | $10.18M | +5.4% |
| Q4 FY2023 | Dec 31, 2023 | $10.13M | -61.3% |
| Q3 FY2023 | Sep 30, 2023 | $9.20M | +626.4% |
| Q2 FY2023 | Jun 30, 2023 | $11.05M | +464.7% |
| Q1 FY2023 | Mar 31, 2023 | $9.66M | +293.4% |
| Q4 FY2022 | Dec 31, 2022 | $26.16M | +51.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.27M | -84.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.96M | -82.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.45M | -75.0% |
| Q4 FY2021 | Dec 31, 2021 | $17.31M | +79.4% |
| Q3 FY2021 | Sep 30, 2021 | $8.06M | -2.3% |
| Q2 FY2021 | Jun 30, 2021 | $11.16M | +104.8% |
| Q1 FY2021 | Mar 31, 2021 | $9.83M | +8.5% |
| Q4 FY2020 | Dec 31, 2020 | $9.65M | +128.8% |
| Q3 FY2020 | Sep 30, 2020 | $8.25M | +6.8% |
| Q2 FY2020 | Jun 30, 2020 | $5.45M | -13.1% |
| Q1 FY2020 | Mar 31, 2020 | $9.06M | +50.7% |
| Q4 FY2019 | Dec 31, 2019 | $4.22M | -27.8% |
| Q3 FY2019 | Sep 30, 2019 | $7.73M | +34.3% |
| Q2 FY2019 | Jun 30, 2019 | $6.27M | +14.0% |
| Q1 FY2019 | Mar 31, 2019 | $6.01M | +25.0% |
| Q4 FY2018 | Dec 31, 2018 | $5.83M | +33.5% |
| Q3 FY2018 | Sep 30, 2018 | $5.75M | +36.9% |
| Q2 FY2018 | Jun 30, 2018 | $5.50M | +42.7% |
| Q1 FY2018 | Mar 31, 2018 | $4.81M | +38.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.37M | +40.0% |
| Q3 FY2017 | Sep 30, 2017 | $4.20M | +26.7% |
| Q2 FY2017 | Jun 30, 2017 | $3.86M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.47M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.12M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.32M | – |
See a number that looks wrong?